Oncotarget

A new research paper was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma.” The human Lymphocyte antigen-6 (LY6) gene family has recently gained interest for its possible role in tumor progression. In this new study, researchers Luke A. Rathbun, Anthony M. Ma...

A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.” In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja, Mahinbanu Mammadii, Faiz Anwer, Shahzad Raza, and Chakra P. Chaulagain from SUNY Upstate Medi...

A new research perspective was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism.” Colon cancer (CRC) is one of the most common malignancies and is a leading cause of cancer-related deaths worldwide. While the tumor microenvironment (TME) suppo...

A new research perspective was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Crossroads: the role of biomarkers in the management of lumps in the breast.” Here, Dr. Georg F. Weber from the University of Cincinnati Academic Health Center discusses a long-standing issue in women’s health: lumps in the breast. Women over the age of 40 years often have lumps in their breasts that a...

Listen to a blog summary of an editorial perspective that was published in Oncotarget’s Volume 14, entitled, “EGFR endocytosis: more than meets the eye.” _________________________________ EGFR (epidermal growth factor receptor) is a crucial protein that plays a significant role in various biological processes such as cell growth, proliferation, differentiation, and survival. Dysregulation of EGFR...

A new research paper was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Differential silencing of STAT3 isoforms leads to changes in STAT3 activation.” Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in multiple fundamental biological processes and a key player in cancer development and progression. STAT3 is activated upon tyrosine p...

A new editorial paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, “Tumor necroptosis promotes metastasis through modulating the interplay between tumor and host immunity.” In this new editorial, researchers Zhaoshan Liu, Swati Choksi and Zheng-Gang Liu from the National Institutes of Health’s National Cancer Institute discuss cell death—which can happen as finely regulated...

A new research paper was published in Oncotarget's Volume 14 on April 15, 2023, entitled, “Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.” Duodenal adenocarcinoma (DA) is a rare malignancy without validated tumor markers. In practice, carcinoembryonic antigen...

Listen to a blog summary of an editorial published in Oncotarget on March 21, 2023, entitled, “Therapy drives genomic evolution in metastatic cancer. _________________________________________________ There are several theories that attempt to explain the genesis of cancer. One prominent theory is the genetic theory—proposing that cancer may arise from the accumulation of genetic mutations that alt...

A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “Cancer prevention with rapamycin.” The mTOR (Target of Rapamycin) pathway is involved in both cancer and aging. Furthermore, common cancers are age-related diseases, and their incidence increases exponentially with age. In his new research perspective, Mikhail V. Blagosklonny, M.D., Ph. D., from Roswel...

A new research paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, “A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.” Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release, showed synergistic antitumor activity in combinat...

A new review paper was published in Oncotarget's Volume 14 on March 31, 2023, entitled, “Crosstalk between triple negative breast cancer and microenvironment.” Although many advances have been made in the treatment of breast cancer, for triple negative breast cancer (TNBC) these therapies have not significantly increased overall survival. Tumor microenvironment (TME) plays an essential role to dev...

A new editorial perspective was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Cancer-associated fibroblasts: challenges and opportunities.” Cancer-associated fibroblasts (CAFs) are a type of cell that plays a key role in the tumor microenvironment. While these cells have been extensively studied, their precise role in cancer development and progression is still not fully unders...

A new editorial paper was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.” In this editorial, researchers Kamrul Hasan and Thomas J. Kipps from the University of California discuss cortactin—an intracellular cytoskeletal protein that can undergo tyrosine phosphorylation upon external stimulation and promot...

Impact Journals (Oncotarget's publisher) will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 from April 14-19 at the Orange County Convention Center in Orlando, Florida. This year, the AACR meeting theme is: “Advancing the Frontiers of Cancer Science and Medicine.” Impact Journals publishes scholarly journals in the biomedical sciences w...

Listen to a blog summary of an editorial in Volume 14, entitled, “Proof-of-principle: targeted childhood leukemia prevention.” ___________________________________________ Childhood leukemia is a devastating disease that affects thousands of children every year. Despite significant advancements in the field of pediatric oncology, childhood leukemia remains a major cause of morbidity and mortality i...

A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.” Abnormal expression of bicellular tight junction claudins, including claudin-2 are observed during carcinogenesis in human lung adenocar...

A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.” Finding effective therapies against cancers driven by mutant and/or overexpressed hyperactive G-proteins remains an area of active research. Polyisoprenylated cysteinyl am...

A new research paper was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.” Glypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior has been discussed in different cancer types. In this recent cancer-wide GPC expressi...

A new editorial paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis.” Over the last 40 years, the complex genetic landscape, the heterogeneity of the microenvironment and the cell plasticity of Osteosarcoma (OSA) tumors have delayed the therapeutic and prognostic stratific...

Blog summary of an editorial perspective published in Oncotarget on entitled, “Leakage? or Secretion? unconventional protein secretion in cancer.” ________________________________________ Conventional protein secretion is fairly well understood in this day and age. Proteins that are secreted through the classical, secretory vesicle-related pathway contain a signal peptide that guides them to the e...

A new research paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss.” Homozygous deletion of methylthioadenosine phosphorylase (MTAP) upregulates de novo synthesis of purine (DNSP) and increases the proliferation of neoplastic cells. This increases the sensitivity...

A new review paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.” Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. In his latest review, Mikhail V. Blagosklonny, M.D., Ph. D., from Roswell Park Comprehensive Cancer Center discusses the...

A new editorial paper was published in Oncotarget's Volume 14 on February 25, 2023, entitled, “Mitochondria engage the integrated stress response to promote tumor growth.” In this new editorial, researchers Dillon P. Boulton and M. Cecilia Caino from the University of Colorado School of Medicine discussed prostate cancer (PCa)—the most diagnosed and second deadliest cancer among men in the United...

A new review paper was published in Oncotarget's Volume 14 on February 25, 2023, entitled, “What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types.” Since its inception, the Hemoglobin, Albumin, Lymphocyte, Platelet (HALP) Score has gained attention as a new prognostic biomarker to predict several cli...